Pharmacological benefit of I1-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease

Brain Research Bulletin

Volumn 102, Issue , 2014, Pages 57-68

  Gupta, Surbhi ^a   Sharma, Bhupesh ^a,b  

^a BHARAT INSTITUTE OF TECHNOLOGY   (India)

^b Dilshad Garden   (India)

Author keywords

3 Nitropropionic acid; Mitochondrial enzyme complex; Moxonidine; Natrium diethyl dithio carbamate trihydrate; Tetrabenazine

Indexed keywords

3 NITROPROPIONIC ACID; ACETYLCHOLINESTERASE; CATALASE; IMIDAZOLINE I1 RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID PEROXIDE; MITOCHONDRIAL ENZYME; MOXONIDINE; NATRIUM DIETHYL DITHIO CARBAMATE TRIHYDRATE; NEUROPROTECTIVE AGENT; NITRATE; NITRIC OXIDE; NITRITE; SUPEROXIDE DISMUTASE; TETRABENAZINE; UNCLASSIFIED DRUG; 3-NITROPROPIONIC ACID; ADRENERGIC RECEPTOR AFFECTING AGENT; DIETHYLDITHIOCARBAMIC ACID; IMIDAZOLE DERIVATIVE; IMIDAZOLINE I1 RECEPTORS; IMIDAZOLINE RECEPTOR; NITRO DERIVATIVE; NOOTROPIC AGENT; PROPIONIC ACID DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BODY WEIGHT; BRAIN HOMOGENATE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; CORPUS STRIATUM; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; GRIP STRENGTH; HUNTINGTON CHOREA; LEARNING; LEARNING DISORDER; LOCOMOTION; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOTOR COORDINATION; MOUSE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; ETIOLOGY; HUNTINGTON DISEASE; LEARNING DISORDERS; MEMORY DISORDERS; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; WISTAR RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANXIETY; BRAIN; DISEASE MODELS, ANIMAL; DITIOCARB; HUNTINGTON DISEASE; IMIDAZOLES; IMIDAZOLINE RECEPTORS; LEARNING DISORDERS; MEMORY DISORDERS; MOTOR ACTIVITY; NF-KAPPA B; NITRO COMPOUNDS; NOOTROPIC AGENTS; OXIDATIVE STRESS; PROPIONATES; RATS; RATS, WISTAR; TETRABENAZINE;

EID: 84896369259     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2014.02.007     Document Type: Article

References (73)

1. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
2. Andersson D.R., Nissbrandt H., Bergquist F. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur. J. Neurosci. 2006, 24:617-624.
3. Anthony J.D., Gary L.P., Lisa A.L., Douglas R.S. Role of NFκB in age-related vascular endothelial dysfunction in humans. Aging 2009, 1:678-680.
4. Beauchamp C., Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 1971, 44:276-287.
5. Ben, M'Barek K., Pla P., Orvoen S., Benstaali C., Godin J.D., Gardier A.M., Saudou F., David D.J., Humbert S. Huntingtin mediates anxiety/depression-related behaviors and hippocampal neurogenesis. J. Neurosci. 2013, 33:8608-8620.
6. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73:1127-1137.
7. Bertoni A., Giuliano P., Galgani M., Rotoli D., Ulianich L., Adornetto A., Santillo M.R., Porcellini A., Avvedimento V.E. Early and late events induced by polyQ-expanded proteins, identification of a common pathogenic property of polYQ-expanded proteins. J. Biol. Chem. 2011, 286:4727-4741.
8. Bhateja D.K., Dhull D.K., Gill A., Sidhu A., Sharma S., Reddy B.V., Padi S.S. Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats, possible neuroprotective mechanisms. Eur. J. Pharmacol. 2012, 674:33-43.
9. Bing C., King P., Pickavance L., Brown M., Ziegler D., Kaan E., Williams G. The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. Br. J. Pharmacol. 1999, 127:35-42.
10. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., Roy D.S., Rosen B.R., Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 1993, 60:356-359.
11. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., Greengard P., Hipskind R.A., Borrelli E., Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 2001, 21:5110-5120.
12. Chen J.J., Ondo W.G., Dashtipour K., Swope D.M. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin. Ther. 2012, 34:1487-1504.
13. Chiarugi A. Characterization of the molecular events following impairment of NF-kappaB-driven transcription in neurons. Brain Res. Mol. Brain Res. 2002, 109:179-188.
14. Chiu C.T., Liu G., Leeds P., Chuang D.M. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 2011, 36:2406-2421.
15. Ciubotariu D., Nechifor M. Involvement of imidazoline system in drug addiction. Rev. Med. Chir. Soc. Med. Nat. Iasi 2012, 116:1118-1122.
16. Colle D., Hartwig J.M., Soares F.A., Farina M. Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. Brain Res. Bull. 2012, 87:397-405.
17. Dalbem A., Silveira C.V., Pedroso M.F., Breda R.V., Werne, Baes C.V., Bartmann A.P., da Costa J.C. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease. Brain Res. 2005, 1047:148-158.
18. Dorresteijn J.A., Schrover I.M., Visseren F.L., Scheffer P.G., Oey P.L., Danser A.H., Spiering W. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J. Hypertens. 2013, 31:393-403.
19. Farrar A.M., Callahan J.W., Abercrombie E.D. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms. Exp. Neurol. 2011, 232:119-125.
20. Forster M., Dubey A., Dawson K., Stutts W., Lal H., Sohal R. Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc. Natl. Acad. Sci. U. S. A. 1996, 88:3633-3636.
21. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009, 9:62.
22. Frussa-Filho R., Otoboni J.R., Uema F.T., Sá-Rocha L.C. Evaluation of memory and anxiety in rats observed in the elevated plus-maze: effects of age and isolation. Braz. J. Med. Biol. Res. 1991, 24:725-728.
23. Gopinath K., Sudhandiran G. Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neuroscience 2012, 227:134-143.
24. Gros Y., Schuldiner S. Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter. J. Biol. Chem. 2010, 285:5076-5084.
25. Gupta S., Sharma B. Pharmacological modulation of I1-imidazoline and α2-adrenoceptors in sub acute brain ischemia induced vascular dementia. Eur. J. Pharmacol. 2014, 15(723):80-90.
26. Haider S., Batool Z., Haleem D.J. Nootropic and hypophagic effects following long term intake of almonds (Prunusamygdalus) in rats. Nutr. Hosp. 2012, 27:2109-2115.
27. Han I., You Y., Kordower J.H., Brady S.T., Morfini G.A. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J. Neurochem. 2010, 113:1073-1091.
28. Haxhiu M.A., Dreshaj I.A., McFadden C.B., Erokwu B.O., Ernsberger P. I1-imidazoline receptors and cholinergic outflow to the airways. J. Auton. Nerv. Syst. 1998, 71:167-174.
29. Hult, Lundh S., Nilsson N., Soylu R., Kirik D., Petersén Å. Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2013, 22:3485-3497.
30. Imielski Y., Schwamborn J.C., Lüningschrör P., Heimann P., Holzberg M., Werner H., Leske O., Püschel A.W., Memet S., Heumann R., Israel A., Kaltschmidt C., Kaltschmidt B. Regrowing the adult brain: NF-κB controls functional circuit formation and tissue homeostasis in the dentate gyrus. PLoS One 2012, 7:e30838. 10.1371/journal.pone.0030838.
31. Itoh J., Nabeshima T., Kameyama T. Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur. J. Pharmacol. 1991, 194:71-76.
32. Kaltschmidt B., Ndiaye D., Korte M., Pothion S., Arbibe L., Prullage M., Pfeiffer J., Lindecke A., Staiger V., Israel A., et al. NF-κB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol. Cell. Biol. 2006, 26:2936-2946.
33. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294:1030-1038.
34. King T.E. Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol. 1967, 10:322-331.
35. King T.E., Howard R.L. Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol. 1967, 10:275-284.
36. Kleniewska P., Piechota-Polanczyk A., Michalski L., Michalska M., Balcerczak E., Zebrowska M., Goraca A. Influence of block of NF-kappa B signaling pathway on oxidative stress in the liver homogenates. Oxid. Med. Cell Longev. 2013, 2013:308358. DOI: 10.1155/2013/308358.
37. Konagaya M., Konagaya Y., Iida M. CSF acetylcholinesterase activity in central neurological diseases involving cholinergic systems. Rinsho. Shinkeigaku 1992, 32:266-271.
38. Kuhad A., Bishnoi M., Tiwari V., Chopra K. Suppression of NFkappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol. Biochem. Behav. 2009, 92:251-259.
39. Kumar P., Kalonia H., Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br. J. Pharmacol. 2011, 164:644-654.
40. Kumar P., Kumar A. Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid-induced behavioral alterations and oxidative stress in rats. Pharmacol. Rep. 2008, 5:706-715.
41. Lee J.Y., Kim H.S., Choi H.Y., Oh T.H., Yune T.Y. Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury. Brain 2012, 135:2375-2389.
42. Luo J., Phan T.X., Yang Y., Garelick M.G., Storm D.R. Increases in cAMP. MAPK activity, and CREB phosphorylation during REM sleep: implications for REM sleep and memory consolidation. J. Neurosci. 2013, 33:6460-6468.
43. Mandavilli B.S., Boldogh I.Van., Houten B. 3-Nitropropionic acid-induced hydrogen peroxide, mitochondrial DNA damage, and cell death are attenuated by Bcl-2 overexpression in PC12 cells. Brain Res. Mol. Brain Res. 2005, 133:215-223.
44. Mattson M.P., Meffert M.K. Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
45. Meyer A.C., Horton D.B., Neugebauer N.M., Wooters T.E., Nickell J.R., Dwoskin L.P., Bardo M.T. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology 2011, 61:849-856.
46. Milusheva E., Sperlágh B., Shikova L., Baranyi M., Tretter L., Adám-Vizi V., Vizi E.S. Non-synaptic release of [3H]noradrenaline in response to oxidative stress combined with mitochondrial dysfunction in rat hippocampal slices. Neuroscience 2003, 120:771-781.
47. Napolitano M., Zei D., Centonze D., Palermo R., Bernardi G., Vacca A., Calabresi P., Gulino A. NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease. Neurosci. Lett. 2008, 434:241-246.
48. Narboux-Nême N., Sagné C., Doly S., Diaz S.L., Martin C.B., Angenard G., Martres M.P., Giros B., Hamon M., Lanfumey L., Gaspar P., Mongeau R. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences. Neuropsychopharmacology 2011, 36:2538-2550.
49. Nasr M.A., El-Gowilly S.M., El-Mas M.M. Comparable renovascular protective effects of moxonidine and simvastatin in rats exposed to cigarette smoke. Vascul. Pharmacol. 2010, 53:53-60.
50. Nechifor M., Ciubotariu D. Behavioral involvement of imidazoline system. Rev. Med. Chir. Soc. Med. Nat. Iasi 2012, 116:552-556.
51. Nikolic K., Agbaba D. Imidazoline antihypertensive drugs: selective i(1)-imidazoline receptors activation. Cardiovasc. Ther. 2012, 30:209-216.
52. Ostroumova O.D., Mamaev V.I., Bagramova IuA., Rybkina T.E., Kuz'michev I.A. Use of phisiotens for the treatment of arterial hypertension in elderly patients. Ter. Arkh. 2001, 73:17-22.
53. Otani A., Ishihara S., Aziz M.M., Oshima N., Mishima Y., Moriyama I., Yuki T., Amano Y., Ansary M.M., Kinoshita Y. Intrarectal administration of milk fat globule epidermal growth factor-8 protein ameliorates murine experimental colitis. Int. J. Mol. Med. 2012, 29:349-356.
54. Pandey M., Varghese M., Sindhu K.M., Sreetama S., Navneet A.K., Mohanakumar K.P., Usha R. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J. Neurochem 2008, 104:420-434.
55. Papapetropoulos S., Singer C. Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. Head Face Med. 2006, 2:47.
56. Przybyla-Zawislak B.D., Thorn B.T., Ali S.F., Dennis R.A., Amato A., Virmani A., Binienda Z.K. Identification of rat hippocampal mRNAs altered by the mitochondrial toxicant, 3-NPA. Ann. N. Y. Acad. Sci. 2005, 1053:162-173.
57. Raasch W., Chun K.R.J., Dendorfer A., Dominiak P. Positive inotropic effects of imidazoline derivatives are not mediated via imidazoline binding sites but alpha1-adrenergic receptors. Jpn. J. Pharmacol. 2000, 84:1-6.
58. Renoir T., Pang T.Y., Mo C., Chan G., Chevarin C., Lanfumey L., Hannan A.J. Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice. J. Physiol. 2013, 591:41-55.
59. Sharma A.C., Kulkarni S.K. Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 1992, 16:117-125.
60. Sharma B., Singh N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berl.) 2011, 215:677-687.
61. Sharma B., Singh N. Salutary effect of NFκB inhibitor and folacin in hyperhomocysteinemia-hyperlipidemia induced vascular dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 38:207-215.
62. Sharma B., Singh N. Defensive effect of natrium diethyldithiocarbamate trihydrate (NDDCT) and lisinopril in DOCA-salt hypertension-induced vascular dementia in rats. Psychopharmacology (Berl.) 2012, 223:307-317.
63. Sharma B., Singh N. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, convalesce behavior and biochemistry of hypertension induced vascular dementia in rats. Pharmacol. Biochem. Behav. 2013, 103:821-830.
64. Sharma B., Singh N., Singh M. Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. J. Psychopharmacol. 2008, 22:162-171.
65. Shivasharan B.D., Nagakannan P., Thippeswamy B.S., Veerapur V.P., Bansal P., Unnikrishnan M.K. Protective effect of Calendula officinalis Linn. flowers against 3-nitropropionic acid induced experimental Huntington's disease in rats. Drug Chem. Toxicol. 2013, 36:466-473.
66. Sottocasa G.L., Kuylenstierna B., Ernster L., Bergstrand A. An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J. Cell Biol. 1967, 32:415-438.
67. Taksande B.G., Kotagale N.R., Patel M.R., Shelkar G.P., Ugale R.R., Chopde C.T. Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. Eur. J. Pharmacol. 2010, 637:89-101.
68. Wesnes K., Simpson P.M., Jansson B., Grahnén A., Weimann H.J., Küppers H. Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Eur. J. Clin. Pharmacol. 1997, 52:351-358.
69. Williams A., Sarkar S., Cuddon P., Ttofi E.K., Saiki S., Siddiqi F.H., Jahreiss L., Fleming A., Pask D., Goldsmith P., O'Kane C.J., Floto R.A., Rubinsztein D.C. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 2008, 4:295-305.
70. Yakovleva T., Bazov I., Watanabe H., Hauser K.F., Bakalkin G. Transcriptional control of maladaptive and protective responses in alcoholics: a role of the NF-κB system. Brain Behav. Immun. 2011, 25:S29-S38.
71. Yu-Taeger L., Petrasch-Parwez E., Osmand A.P., Redensek A., Metzger S., Clemens L.E., Park L., Howland D., Calaminus C., Gu X., Pichler B., Yang X.W., Riess O., Nguyen H.P. A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J. Neurosci. 2012, 32:15426-15438.
72. Zeidan M.P., Zomkowski A.D., Rosa A.O., Rodrigues A.L., Gabilan N.H. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur. J. Pharmacol. 2007, 565:125-131.
73. Zhang J., Abdel-Rahman A.A. Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (i1)-receptor-mediated hypotension. J. Pharmacol. Exp. Ther. 2005, 314:945-952.